Search

Displaying results 4491 - 4500 of 10000 in total
  1. Target

    Relaxin receptor 2

    go.drugbank.com/bio_entities/BE0017729
    TargetHumans

    Receptor for relaxin. The activity of this receptor is mediated by G proteins leading to stimulation of adenylate cyclase and an increase of cAMP. May also be a receptor for Leydig insulin-like peptide (INSL3)

    Synonyms: Leucine-rich repeat-containing G protein-coupled receptor 8
  2. Drug

    RTP-801i

    go.drugbank.com/drugs/DB06048
    Investigational

    RTP-801i is an siRNA drug candidate designed to inhibit the expression of the hypoxia-inducible gene RTP801.

  3. Drug

    Quaternium-18

    go.drugbank.com/drugs/DB11305
    ApprovedWithdrawn

    These compounds are poorly absorbed through the skin. Acute oral and percutaneous toxicity tests in animals indicate that they exhibit little or no systemic toxic effects.

  4. Drug

    TA-NIC

    go.drugbank.com/drugs/DB05445
    Investigational

    TA-NIC is a novel and proprietary vaccine in development as an aid to quitting smoking in motivated patients. … It is designed to raise anti-nicotine antibodies which bind to nicotine molecules in the patient's blood stream, reducing the rate and quantity of nicotine entry into the brain, to reduce the addictive

    Categories: Complex Mixtures
  5. Drug

    C31G

    go.drugbank.com/drugs/DB05398
    Investigational

    is a potent broad spectrum antimicrobial agent, effective against gram positive and gram negative bacteria, yeast and fungi.C31G, vaginal gel is developed by Biosyn Inc. and has commenced enrollment in

  6. Drug

    Lancovutide

    go.drugbank.com/drugs/DB05029
    Investigational

    Lancovutide, a peptide antibiotic, is in clinical development for the treatment of cystic fibrosis.

  7. Drug

    Epinastine

    go.drugbank.com/drugs/DB00751
    Approved

    It has a multi-action effect that inhibits the allergic response in 3 ways: 1. stabilizes mast cells by preventing mast cell degranulation to control the allergic response, 2. prevents histamine binding

  8. Drug

    NP2

    go.drugbank.com/drugs/DB06308
    Investigational

    It was under investigation in clinical trial NCT01291901 (NP2 Enkephalin For Treatment of Intractable Cancer Pain).

  9. Drug

    NLX-P101

    go.drugbank.com/drugs/DB05924
    Experimental

    which is overactive in patients with Parkinson’s disease. … The gene is glutamic acid decarboxylase (GAD), whose product synthesizes the major inhibitory neurotransmitter in the brain, (gamma)-aminobutyric acid (GABA), and targets the subthalamic nucleus (STN),

  10. Drug

    Olmutinib

    go.drugbank.com/drugs/DB13164
    Investigational

    Olmutinib recieved breakthrough therapy designation in the United States in December 2015 and was approved for use in Korea in May 2016. … Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer.